title: Optimal strategies for the management of antiplatelet and anticoagulation medications prior to cardiac device implantation.
abstract: Choosing the optimal management strategy for antiplatelet and anticoagulation medications at the time of cardiac device implantation can be challenging. Simply withholding or reversing these medications puts patients at risk of subsequent thromboembolic events. Equally, continuing these medications may unnecessarily increase the risk of bleeding complications. This article summarizes recent findings and provides compelling evidence challenging current recommendations outlined by various professional organizations.
authors.affiliation: Cardiology Division -- Electrophysiology, University of Rochester Medical Center, Rochester, NY, USA. christine_tompkins@urmc.rochester.edu
authors.forename: Christine
authors.initials: C
authors.lastname: Tompkins
authors.forename: Charles A
authors.initials: CA
authors.lastname: Henrikson
mesh_terms: D000925:Anticoagulants / Q000008:administration & dosage* / Q000009:adverse effects; D006348:Cardiac Surgical Procedures / Q000009:adverse effects / Q000295:instrumentation*; D017147:Defibrillators, Implantable; D004334:Drug Administration Schedule; D019317:Evidence-Based Medicine; D006470:Hemorrhage / Q000139:chemically induced; D006801:Humans; D010138:Pacemaker, Artificial; D019990:Perioperative Care; D010975:Platelet Aggregation Inhibitors / Q000008:administration & dosage* / Q000009:adverse effects; D017410:Practice Guidelines as Topic; D013923:Thromboembolism / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants; D010975:Platelet Aggregation Inhibitors